PTK2 and neoplasm: As inhibition of the angiogenic activities of endothelial cells has been observed following administration of FAK inhibitors [20], it is possible that the anti-angiogenic effects associated with FAK inhibition may also contribute to the potent inhibition in tumor growth we observed following treatment with both erlotinib and PF-271.